8月20日中银创新医疗混合A净值下跌2.30%，近1个月累计上涨2.96%

Core Viewpoint - The Zhongyin Innovation Medical Mixed A Fund (007718) has shown significant performance in recent months, with a notable year-to-date return of 86.41%, ranking 31 out of 3882 in its category [1]. Fund Performance - The latest net value of the fund is 2.2431 yuan, reflecting a decrease of 2.30% [1]. - Over the past month, the fund achieved a return of 2.96%, ranking 3737 out of 4049 [1]. - In the last six months, the fund's return was 77.59%, ranking 28 out of 3916 [1]. - Year-to-date, the fund's return stands at 86.41%, ranking 31 out of 3882 [1]. Fund Holdings - The top ten stock holdings of the fund account for a total of 62.83%, with the following key positions: - Innovent Biologics: 8.33% - Kelun-Biotech: 8.15% - Hansoh Pharmaceutical: 8.08% - CanSino Biologics: 8.07% - New Horizon Health: 6.13% - Baillie Gifford: 5.99% - BeiGene: 5.97% - Hengrui Medicine: 4.15% - Rongchang Biologics: 4.05% - ConvaTec: 3.91% [1]. Fund Manager Background - Zheng Ning, the fund manager, has a strong background in the investment field, having previously worked as a stock research manager at Taikang Asset Management and as a senior researcher at Zhonggeng Fund Management [2]. - Zheng joined Zhongyin Fund Management in 2022 and has been managing the Zhongyin Innovation Medical Mixed Fund since July 1, 2022 [2].